Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGF2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
IGF2 siRNA is a small interfering RNA designed to silence the expression of insulin-like growth factor 2 (IGF2). In preclinical research, it has been investigated for its potential to treat neuropathic pain by reducing IGF2 levels in the spinal cord, which has been shown to attenuate mechanical and cold allodynia in rat models. It has also been utilized as a research tool to study the role of IGF2 in depression-like behavior and tumor-induced bone resorption (osteoclastogenesis). The molecule functions by binding to and promoting the degradation of IGF2 mRNA through the RNA-induced silencing complex (RISC), thereby preventing the translation of the IGF2 protein and inhibiting its downstream signaling pathways.
- Other names
- insulin-like growth factor 2 siRNAIGF-II siRNAIGF-2 siRNAIGF2 siRNAIGF 2 siRNA
02
Targets
IGF2 (Insulin-like growth factor 2)
Beyond the preview
Go deeper on IGF2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGF2 siRNA.